BioPharmaTrend
Latest Insights
Companies
  • Companies Directory
  • Case Studies
Newsletter
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
 
 Subscribe 
Sign in
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Business Intelligence
Back to Companies Directory

CytoReason

CytoReason logo

Website
http://www.cytoreason.com
Founded
2016

Technologies

AI Companies (Drug Discovery)

CytoReason turns human clinical data into clear biology, to deliver data-driven target discovery and drug development. CytoReason’s access to unmatched proprietary and public data, combined with cutting-edge machine learning technologies, creates our unique biological models of disease, tissue and drug. Using our molecular-level disease models we turn human clinical data into biology, mapping what the cells, genes and proteins are doing in a disease, tissue and treatment environment. This enables us to uncover disease and drug mechanisms of action and turn that biology into clinical edge, by delivering valuable IP in the form of novel targets, indications, combinations and biomarkers.

data mining drug discovery


Articles Mentioning This Company

How Big Pharma Adopts AI To Boost Drug Discovery

How Big Pharma Adopts AI To Boost Drug Discovery

Oct. 9, 2025     Articles
(Last updated: October 2025) Since 1950, when Alan Turing introduced the concept of 'thinking machines', artificial intelligence has steadily advanced—from the rise of neural networks in the 1980s to the release of OpenAI’s GPT-3 in 2020, which paved the way for ChatGPT in 2022. Today, AI has become an integral …

What Makes Israel's Life Sciences Ecosystem Successful?

Oct. 26, 2022     Articles
Israel's biotech sector has been considered secondary to its thriving Medtech field for decades. Still, the turn of millennia brought a significant shift to the biotech landscape in the country. Part of the growth originates from Israel’s focus on building a solid education with roughly 6% of GDP being spent on …

R&D Platform

The first cell-centered computational model of human disease

News

  • 2024-07-17
    CytoReason Secures $80 Million to Advance AI Disease Models

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Press & Citations
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Topics


  • News
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures

Explore


  • Premium Insights
  • Business Intelligence
  • Companies
  • Events
  • Authors

Partner


  • Sponsorship
  • Editorial Calendar

© WTMB Research & Media, S.L. (WTMB Group)   2026
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.